Skip to main contentBack to Top

The unifying theme of the Tumor Signaling & Angiogenesis program is to build translational clinical trials based on innovative and novel research projects that focus on signaling cascades leading to uncontrolled cell growth and resistance to apoptosis.

The program goals are to identify dysregulated molecular signaling pathways that can be used as cancer-specific targets. Collectively the members of this program work cooperatively to study a variety of kinase targets involved in cancer cell proliferation and progression.

Targets identified in this program can be exploited to develop innovative approaches to cancer prevention and therapy that can be translated into clinical trials. The research into cancer cell signaling incorporates animal models in breast and colon cancer, as well as the pediatric cancer neuroblastoma, to study how specific signaling pathways are involved in the progression of cancer.

Program Members

 

Han-Fei Ding, PhD

Professor

llen K. LeMosy, MD, PhD

Associate Professor

Honglin Li, PhD

Associate Professor

Betty Pace, MD

Professor

Daitoku Sakamuro, PhD

Associate Professor

Patricia V. Schoenlein, PhD

Associate Professor

Muthusamy Thangaraju, PhD

Associate Professor

Guangyu Wu, PhD

Professor
 

Cancer Research News

Doctor at computer

Structural framework for tumors also provides immune protection

Aggressive colorectal cancers set up an interactive network of checkpoints to keep the immune system at bay, scientists report.

Man with big block of ice

Sydenstricker’s blood transfusion research a century ago led to modern methods of tissue banking

In the early part of the last century, blood transfusions occurred directly from the donor to patient. Virgil Sydenstricker found a better way, and it's still in use today.

man sitting next to computer

National veteran dataset will help dissect mental illness, prostate cancer connections

There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.

three people in lab

Standard pathology tests outperform molecular subtyping in bladder cancer

While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found that sophisticated new subtyping techniques designed to do this provide no better information than long-standing pathology tests.